In addition, sDel-1 treatment reduced the phosphorylation of Smad3, indicating that TGF-β signaling is active in the tissues with BLM-induced PF, but that activation is reduced upon Del-1 supplementation (Figure 5D). The gene discussed is EDIL3; the disease is Bloom syndrome.